Home / Products / API / Details
video
Roflumilast Powder

Roflumilast Powder

Appearance: White To Off White Powder
Specification: 99% min
CAS: 162401-32-3
Molecular Formula: C17H14Cl2F2N2O3
Molecular Weight: 403.2075
Shelf Life: 2 Years Proper Storage
Stock: Adequate Stock
Certificate: COA,ISO,GMP, HACCP,SGS
Service: OEM Service(Private Package)

Product Introduction

Xi'an Sonwu Biotech Co., Ltd. is one of the most professional manufacturers and suppliers of roflumilast powder in China. We warmly welcome yuo to wholesale bulk roflumilast powder for sale here from our factory. Quality products and reasonable price are available.

 

What Class Of Chemical Is Roflumilast

Roflumilast powder is a phosphodiesterase-4 (PDE4) inhibitor, mainly used for severe chronic obstructive pulmonary disease and cough with excessive mucus bronchitis, wheezing bronchitis, bronchial asthma, acute and chronic bronchitis with abnormal respiratory secretions, and airbag inflammation. Traditional drugs for the treatment of COPD mainly include bronchodilators and inhaled glucocorticoids. Still, their effects primarily focus on relieving symptoms and improving lung function while controlling chronic airway inflammation is relatively limited. As a systemic anti-inflammatory drug, roflumilast fills this gap and provides a new option for the comprehensive treatment of COPD. Its treatment goal is to reduce the frequency and severity of acute exacerbations of COPD rather than for immediate relief of symptoms. Compared with traditional COPD treatment drugs (such as LABA, LAMA and ICS), daxas emphasizes systemic anti-inflammatory effects, can effectively reduce the frequency of acute exacerbations, and has unique efficacy for patients with chronic bronchitis phenotype. The anti-inflammatory mechanism of action of daxas makes it potentially suitable for other inflammatory diseases such as asthma, idiopathic pulmonary fibrosis (IPF) and inflammatory bowel disease (IBD). daxas powder, produced by Xi'an Sonwu, has passed third-party testing and certification tests such as SGS and HPLC. Xi'an Sonwu provides online and timely service; click the email to get raw materials.

Roflumilast structure

 

Certificate Of Analysis

Items

Specification

Results

Appearance

White to off white powder

Complies

Identification

By IR

Complies

By HPLC

Complies

Solubility

DMSO: soluble20mg/mL, clear

Complies

Melting point

158°C

94-95°C

Residual solvents

Dichloromethane: ≤ 100ppm

Complies

Hexame≤ 200 ppm

Not detectable

Ethyl acetate≤500 ppm

Complies

Terahy drofuran≤ 100 ppm

Not detectable

Related substances

Impurity A: ≤ 0.10%

Complies

 

Impurity B: ≤ 0.10%

Complies

 

Any other single impurity≤ 0.10%

Not detectable

 

Total impuritied≤ 0.50%

99.34%

Assay

98.0-102.0%

99.45%

 

Where To Buy Daxas

Xi'an Sonwu Biotech Co., Ltd. is an international trading enterprise, and its trading fields involve countries and regions in the Americas, Asia, Europe, and Oceania. Xi'an Sonwu has nearly ten years of experience in manufacturing and production and has rich experience in product production, testing, sales, and export. Xi'an Songwu has a particular line of transportation in the global trade, and there are a series of strict processes from product production to door-to-door service. Xi'an Sonwu has always adhered to the principle of quality first, pursuing the goal of manufacturing high-quality products at a low cost and seeking the satisfaction of every customer. Based on the above purposes, customers have given good feedback on the products, so if you need daxas powder, please find Xi'an Sonwu.

Xi'an Sonwu not only fully guarantees product quality but also can provide samples. Please check the quantity.

Form

Sample Amount

MOQ

Powder

50g

100g

 

Customers' Good Comment

Customers' Good Comment

 

Why Is Roflumilast Used In COPD

Roflumilast is mainly used to treat chronic obstructive pulmonary disease (COPD) because of its anti-inflammatory properties, which help control the chronic inflammation characteristic of the disease. Prolonged airflow restriction, inflammation, damage, and structural alterations in the lungs and airways are the hallmarks of chronic obstructive pulmonary disease, frequently accompanied by symptoms including coughing, sputum, and dyspnea. The disease is usually progressive and is an irreversible disease that seriously affects the patient's quality of life and can lead to death. Traditional COPD therapies, such as bronchodilators and inhaled corticosteroids, mainly target symptom relief and airway relaxation, but they have limited effect on reducing inflammation, and daxas fills this gap.

 

1. Control chronic airway inflammation

One of the core pathological mechanisms of COPD is chronic inflammation, and daxas effectively inhibits inflammation by inhibiting PDE4 activity, reducing the release of inflammatory factors, and inhibiting airway remodeling. PDE4 is an essential enzyme in inflammatory cells that breaks down cyclic adenosine monophosphate (cAMP). Daxas inhibits PDE4, which raises intracellular cAMP levels. Secondly, it can inhibit the release of inflammatory mediators such as necrosis factor-α (TNF-α), interleukin-8 (IL-8) and leukotriene B4 (LTB4) by neutrophils, macrophages and T lymphocytes. In addition, it can reduce airway wall fibrosis and secretion accumulation, thereby delaying the progression of airway obstruction. This anti-inflammatory effect is particularly significant for the chronic bronchitis phenotype because the inflammatory response of COPD patients with this phenotype is more prominent.

COPD

 

2. Reduce acute exacerbations (AECOPD)

Acute exacerbations are the primary manifestation of COPD deterioration, which may lead to hospitalization, increased mortality and worsening of the long-term course of the disease. Daxas can dramatically lower the incidence of acute exacerbations, according to studies, particularly in patients with moderate to severe COPD and chronic bronchitis. Suppressing airway inflammation and lowering secretions can also lessen the severity of acute exacerbations and slow the sharp deterioration in lung function brought on by acute exacerbations. Daxas is suitable for patients who have received the maximum dose of inhaled therapy (LABA/LAMA or ICS) but still have frequent acute exacerbations.

 

3. Improve lung function

Roflumilast powder can improve airway patency and slightly improve the patient's lung function by reducing inflammatory airway narrowing and secretion blockage. Studies have shown that it can significantly increase FEV1 based on maintenance treatment and enhance the effects of other drugs (such as LABA/LAMA). Although its direct effect on lung function is limited, it can improve lung function more comprehensively when combined with other bronchodilators and ICS.

 

4. Targeting chronic bronchitis phenotype

COPD includes multiple phenotypes, among which the chronic bronchitis phenotype is characterized by excessive mucus secretion, significant inflammatory response, and a high risk of acute exacerbation. This substance precisely targets this by enhancing mucus drainage and lowering inflammation, which lessens exacerbations and offers vital symptom relief.

 

5. Unique advantages of adjuvant therapy

Despite not being a first-line treatment for COPD, it can be utilized as a fallback option if other medications are unsuccessful. For patients who are still poorly controlled even with the maximum dose of inhaled drugs (such as LABA/LAMA/ICS), daxas can significantly improve the condition.

how does Roflumilast work for COPD

 

What Other Uses Does Roflumilast Have

1. Asthma

The effect of it in patients with asthma is mainly through its anti-inflammatory effect. Asthma is closely related to airway inflammation, especially the activity of eosinophils and T cells. Daxas can lessen the release of inflammatory mediators (such as IL-4, IL-5, and IL-13) and activate inflammatory cells. Some studies have shown that it may be effective for some patients with refractory asthma (especially asthma accompanied by neutrophilic inflammation), especially when inhaled corticosteroids (ICS) are ineffective.

Asthma

2. Psoriasis

Inflammation and hyperkeratosis are hallmarks of psoriasis, an immune-mediated skin condition. Daxas may reduce the inflammatory response of psoriasis by regulating PDE4 to inhibit inflammatory factors (such as TNF-α and IL-17). The FDA authorized roflumilast in 2022 for treating individuals with mild to moderate plaque psoriasis because it has demonstrated the ability to alleviate the symptoms of mild to moderate psoriasis when applied topically.

3. Skin diseases

In addition to psoriasis, roflumilasts show specific efficacy in treating other inflammatory skin diseases. For example, in atopic dermatitis (eczema), preliminary studies have shown that it may be effective for patients with eczema, especially those with moderate to mild conditions.

4. Inflammatory bowel disease (IBD)

Inflammatory bowel diseases include Crohn's disease and ulcerative colitis. The pathological mechanisms of these diseases also involve the release of inflammatory factors and excessive immune system responses. By inhibiting inflammatory factors in the intestine (such as TNF-α and IL-23), it may help reduce intestinal inflammation.

Inflammatory bowel disease

5. Neurological diseases

The anti-inflammatory effect of roflumilast has potential therapeutic significance for certain diseases related to neuroinflammation, such as Alzheimer's disease and multiple sclerosis (MS). The pathological mechanism of Alzheimer's disease is closely related to neuroinflammation and oxidative stress. Daxas increases cAMP levels through PDE4 inhibition, which may reduce neuroinflammation and improve cognitive function.

6. Pulmonary arterial hypertension (PAH)

PAH is an elevated pulmonary artery pressure caused by pulmonary vascular remodeling and inflammation. By reducing inflammation and vascular remodeling, it may improve the condition of patients with PAH.

7. Obesity-related diseases

Obesity-related inflammation (such as chronic inflammation of fatty tissue) plays a vital role in insulin resistance and metabolic syndrome. Daxas may improve insulin sensitivity and metabolic status by reducing inflammatory factors.

 

Factory
1. Xi'an Sonwu Biotech Co., Ltd has a factory to produce, manufacture and store the products, so it has adequate stock. Xi'an Sonwu has a well-ordered, clean and tidy production department. Under the leadership of Xi'an Sonwu, researchers can continuously develop high-quality new products.

2. Xi'an Sonwu has strict requirements on personnel allocation from production and testing to sales. To ensure that each product is escorted, rigorous data support and after-sales service are provided.

factory a

factory b

 

Certificates

certificates

 

Packaging

packaging

 

Logistics

Logistics

Besides guaranteeing the product, the other most important thing is customers can receive the goods smoothly. So, Xi'an Sonwu supplies all kinds of couriers according to different needs.

courier

 

FAQ

1. How do you contact Xi'an Sonwu Biotech Co., Ltd.?

You can contact me by email, telephone number, or social media.

2. How can the quality of the product be ensured?

Xi'an Sonwu tests each batch so it can supply COA for customers. The products also pass tests, such as HPLC, UV, GC, TLC, etc. Xi'an Sonwu also cooperates with third parties, like SGS.

3. How to pack and store?

Pack: Vacuum sealed foil packaging & Sealed export-grade drum or pack according to customers ' needs.

Storage: Keep it dry and cool, and avoid intense light and heat.

 

If you want to know the daxas powder price, you can contact Xi'an Sonwu. Click the email, and then you get high-quality roflumilast powder.

Email: sales@sonwu.com

Hot Tags: roflumilast powder, China, suppliers, manufacturers, factory, wholesale, buy, price, bulk, pure, raw, supply, for sale, Desoxycortone Acetate Powder, Urokinase Powder, NAD Powder, PQQ NA2 powder, Chlorin E6, Adenosine Triphosphate Disodium Powder

Send Inquiry

whatsapp

teams

E-mail

Inquiry

Bag